The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey

Basit Öğe Kaydı
dc.authoridAytekin, Sema/0000-0003-1376-1573en_US
dc.authoridÇelik, Gökçen/0000-0002-0032-5572en_US
dc.authoridsolak, eda öksüm/0000-0002-1362-7801en_US
dc.authoridEngin, Burhan/0000-0002-5140-1926en_US
dc.authoridKartal, Selda Pelin/0000-0001-7310-8635en_US
dc.authoridYılmaz, Oğuz/0000-0001-8454-4811en_US
dc.authoridBozdag, Ali/0000-0001-6068-6348en_US
dc.contributor.authorKartal, Selda Pelin
dc.contributor.authorÇelik, Gokcen
dc.contributor.authorYılmaz, Oğuz
dc.contributor.authorOksum Solak, Eda
dc.contributor.authorDemirbag Gül, Busra
dc.contributor.authorUstunbas, Tuba Kevser
dc.contributor.authorGönülal, Melis
dc.date.accessioned2024-07-12T21:37:20Z
dc.date.available2024-07-12T21:37:20Z
dc.date.issued2022en_US
dc.department[Belirlenecek]en_US
dc.description.abstractBackground Immunosuppressive therapy has been a great concern during the pandemic. This study aimed to evaluate the pandemic's impact on psoriasis patients treated with immunosuppressive drugs. Material and Methods The multicenter study was conducted in 14 tertiary dermatology centers. Demographic data, treatment status, disease course, and cases of COVID-19 were evaluated in patients with psoriasis using the immunosuppressive treatment. Results Of 1827 patients included, the drug adherence rate was 68.2%. Those receiving anti-interleukin (anti-IL) drugs were more likely to continue treatment than patients receiving conventional drugs (OR = 1.50, 95% CI, 1.181-1.895, p = .001). Disease worsening rate was 24.2% and drug dose reduction increased this rate 3.26 and drug withdrawal 8.71 times. Receiving anti-TNF or anti-IL drugs was associated with less disease worsening compared to conventional drugs (p = .038, p = .032; respectively). Drug withdrawal causes were 'unable to come' (39.6%), 'COVID concern' (25.3%), and 'physician's and patient's co-decision' (17.4%). Four patients had COVID-19 infection with mild symptoms. The incidence was 0.0022% while it was 0.0025% in the general population. Conclusion Our study shows that psoriasis patients using systemic immunosuppressive do not have a higher, but even lower COVID-19 risk than the general population, and treatment compliance with biological drugs is higher.en_US
dc.identifier.doi10.1080/09546634.2021.1927947
dc.identifier.endpage2144en_US
dc.identifier.issn0954-6634
dc.identifier.issn1471-1753
dc.identifier.issue4en_US
dc.identifier.pmid34030547en_US
dc.identifier.scopus2-s2.0-85106428914en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2137en_US
dc.identifier.urihttps://doi.org/10.1080/09546634.2021.1927947
dc.identifier.urihttps://hdl.handle.net/20.500.12415/6756
dc.identifier.volume33en_US
dc.identifier.wosWOS:000654058700001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Dermatological Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY04098
dc.subjectCovid-19en_US
dc.subjectPsoriasisen_US
dc.subjectImmunosuppressive Drugsen_US
dc.subjectBiologicsen_US
dc.subjectTreatment Adherenceen_US
dc.titleThe impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkeyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu